SCHEDULE: Fortress Biotech: Ownership Filing Confirms Holdings

A Schedule 13G filing confirms the beneficial ownership of Fortress Biotech, Inc. common stock by several entities associated with Millennium Management.

Summary

• This filing is a Schedule 13G, which is an informational filing for passive investors who own more than 5% of a company's stock.
• It confirms that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander are jointly filing regarding their beneficial ownership of Fortress Biotech, Inc. common stock.
• The filing indicates that these entities collectively beneficially own 1,778,133 shares of Fortress Biotech, Inc. common stock, representing 5.3% of the class.
• A joint filing agreement is included, confirming the coordinated filing of this Schedule 13G.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily confirming existing ownership structures and joint filing agreements rather than announcing new material information.

Positives

• Confirms significant passive ownership stake (5.3%) by established investment entities, which can imply confidence in the company's long-term prospects.
• The filing is up-to-date, with a date of event of August 26, 2026, and signatures dated August 31, 2026.

Negatives

• The filing does not provide any new financial performance data or strategic updates, offering no insight into recent operational changes.
• The information is purely informational regarding ownership and does not signal any new investment or strategic shift by the reporting persons.

Risks

• The filing does not explicitly mention any risks associated with Fortress Biotech, Inc. or the reporting persons' holdings.
• Potential for future changes in ownership by these large holders could impact share price, though no such intentions are stated.

Future Outlook

No forward-looking statements or guidance are provided in this ownership filing.

Management Comments

• The filing includes a certification stating that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large institutional investors and indicate a passive investment approach, which is typical in the biotechnology sector where significant stakes can be held by asset managers.

Stakeholder Impact

• Shareholders: The confirmation of a significant passive stake by established investment firms may be viewed positively, suggesting stability in a portion of the ownership base.
• Management: The filing reinforces that the reporting persons are not seeking to influence control, which can provide clarity to the company's board and management.

Next Steps

• The reporting persons will continue to file Schedule 13G as required by regulations based on their ownership levels.

Key Dates

Keywords

Fortress Biotech, Schedule 13G, Beneficial Ownership, Millennium Management, Integrated Core Strategies, Common Stock, Ownership Stake